Long‐term survival analysis of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA levels

BACKGROUND: The objective of this study was to confirm the relation between plasma Epstein‐Barr virus (EBV) DNA (pEBV DNA) load and treatment outcomes after long‐term follow‐up in patients with nasopharyngeal carcinoma (NPC).

[1]  Chong Zhao,et al.  Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  B. O'Sullivan,et al.  A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  B. O'Sullivan,et al.  Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. , 2010, Journal of the National Cancer Institute.

[4]  A. King,et al.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Liang,et al.  Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. , 2008, International journal of radiation oncology, biology, physics.

[6]  Jin-Ching Lin,et al.  Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[7]  S. Leung,et al.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Mariani,et al.  Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. , 2005, Journal of the National Cancer Institute.

[9]  Chong Zhao,et al.  Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Zehnder,et al.  A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma , 2005, Clinical Cancer Research.

[12]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[13]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[15]  S. Leung,et al.  Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early‐stage nasopharyngeal carcinoma of undifferentiated type , 2003, Cancer.

[16]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Leung,et al.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.

[18]  S. Leung,et al.  Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.

[19]  Wen-ying Lee,et al.  Epstein‐Barr virus detection in neck metastases by in‐situ hybridization in fine‐needle aspiration cytologic studies: An aid for differentiating the primary site , 2000, Head and Neck.

[20]  S. Leung,et al.  Plasma Cell‐free Epstein‐Barr Virus DNA Quantitation in Patients with Nasopharyngeal Carcinoma: Correlation with Clinical Staging , 2000, Annals of the New York Academy of Sciences.

[21]  S. Leung,et al.  Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. , 1999, Cancer research.

[22]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[23]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Harn,et al.  Expression of Epstein‐Barr virus‐encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma , 1996, Cancer.

[25]  Vumca I Trial.  Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. , 1996, International journal of radiation oncology, biology, physics.

[26]  I. Su,et al.  Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization: A correlation with WHO histologic subtypes , 1996, Cancer.

[27]  P. Warde,et al.  Role of epstein‐barr virus in fine‐needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma , 1995, Head & neck.

[28]  H. Hsu,et al.  Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. , 1993, Intervirology.

[29]  S. T. Liu,et al.  Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification , 1990, Journal of clinical microbiology.